Company news

Milestone Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

November 2, 2026

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences

October 19, 2026

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

October 9, 2026

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

September 3, 2026

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

September 2, 2026

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

August 27, 2026

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

August 21, 2026

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

August 4, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

July 6, 2026

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST Nasal Spray in Patients with PSVT

April 13, 2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST (etripamil) Nasal Spray in Patients with PSVT

April 13, 2026

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

April 9, 2026

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 7, 2026

Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

March 30, 2026

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

March 20, 2026

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

March 16, 2026

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

March 12, 2026

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

February 26, 2026

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

February 10, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 3, 2026

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

January 26, 2026

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

January 6, 2026

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

December 12, 2025

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

November 12, 2025

Milestone Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

November 5, 2025

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

November 3, 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

October 9, 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

August 19, 2025

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

August 12, 2025

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

July 11, 2025

Milestone Pharmaceuticals Announces Proposed Public Offering

July 11, 2025

Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

July 11, 2025

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

June 16, 2025

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025

FDA Issues Complete Response Letter for Etripamil for PSVT

March 28, 2025

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

March 20, 2025

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

March 13, 2025

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

February 27, 2025

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

February 19, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

January 27, 2025

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

November 11, 2024

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

September 3, 2024

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

August 25, 2024

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

August 7, 2024

Milestone Pharmaceuticals Refreshes Board of Directors

July 14, 2024

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 28, 2024

Older news releases →

Calls

Decks

The 5 newest of 17 decks. Every deck is listed under its year.